<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667563</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-054</org_study_id>
    <secondary_id>U01CA121947</secondary_id>
    <secondary_id>CDR0000593634</secondary_id>
    <nct_id>NCT00667563</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Preventing HPV in HIV-Positive Women in India</brief_title>
  <official_title>A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine Among HIV-Positive Women in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from virus proteins may help the body build an effective immune
      response to prevent cervical cancer.

      PURPOSE: This pilot study is looking at the side effects of a human papillomavirus vaccine
      and how well it works in preventing cervical cancer in women in India with HIV-1 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Assess the safety of the Gardasil® quadrivalent human papillomavirus (HPV) (types 6, 11,
           16,18) virus-like-particle vaccine with vs without prior exposure to one or more of the
           HPV types in the vaccine in HIV-positive women in Chennai, India.

        -  Determine the effect of the vaccine on HIV viral load and CD4+/CD8+ levels in these
           patients.

        -  Determine the proportion of these patients who respond serologically to the HPV vaccine
           and the kinetics of their response.

      Secondary

        -  Determine the prevalence and incidence of cervical intraepithelial neoplasia in these
           patients.

        -  Determine the spectrum of cervical HPV types in these patients at baseline, 9 months,
           and 1 year after vaccination.

      OUTLINE: This is a multicenter study.

      Patients receive quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) recombinant
      vaccine intramuscularly on day 0 and once in weeks 8 and 24.

      Patients undergo cervical cell, buccal cell, and blood sample collection at baseline and
      periodically after vaccination for immunologic and virologic studies. Cervical cytology
      specimens are examined by polymerase chain reaction to detect HPV 6, 11, 16, or 18 DNA, as
      well as 35 other HPV types. Blood samples are analyzed for CD4+/CD8+ cell count, plasma HIV-1
      RNA levels, and serum HPV antibody titers for HPV types 6, 11, 16, and 18. Some plasma
      samples will be stored for future HPV pseudovirion neutralization assays.

      After completion of study therapy, patients are followed periodically for up to 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0</measure>
    <time_frame>52 weeks from study entry</time_frame>
    <description>Number of grade 3 or 4 adverse events attributed to vaccine per 100 patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Significant Decrease (at the 0.05 Significance Level) in CD4+ Cell Count</measure>
    <time_frame>Screening/Week 0, Weeks 2, 10, 26, and 52.</time_frame>
    <description>Significant decrease (at the 0.05 significance level) in CD4+ cell count to 75% of the baseline level on two or more consecutive tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Detectable HPV Antibodies to HPV 16 at Week 28</measure>
    <time_frame>Week 28</time_frame>
    <description>Number of participants with detectable HPV antibody to HPV 16 among those with undetectable antibodies to HPV 16 at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With a Significant Increase in HIV Viral Load</measure>
    <time_frame>Screening/week 0, weeks, 2, 10, 26 and 52</time_frame>
    <description>Number of patients with a significant increase in HIV viral load defined as &gt; 1 log increase in HIV load from baseline on 2 consecutive occasions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Detectable Antibodies to HPV-6</measure>
    <time_frame>28 weeks</time_frame>
    <description>Detectable antibodies to HPV-6 among participant who had undetectable antibodies to HPV-6 at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Detectable Antibodies to HPV-11</measure>
    <time_frame>28 weeks</time_frame>
    <description>Detectable antibodies to HPV-11 among those who had undetectable antibodies to HPV-11 at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Detectable Antibodies to HPV-18</measure>
    <time_frame>28 weeks</time_frame>
    <description>Detectable antibodies to HPV-18 among participants with undetectable antibodies to HPV-18 at baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Nonneoplastic Condition</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Gardasil Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine</intervention_name>
    <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.</description>
    <arm_group_label>Gardasil Vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>Weeks 0, 2, 10, 26, and 52.</description>
    <arm_group_label>Gardasil Vaccination</arm_group_label>
    <other_name>HIV viral load test and HPV neutralization assays.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Screening, week 36, and week 52.</description>
    <arm_group_label>Gardasil Vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
    <description>Screening, week 36, and week 52.</description>
    <arm_group_label>Gardasil Vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colposcopic biopsy</intervention_name>
    <description>Screening, week 36, and week 52.</description>
    <arm_group_label>Gardasil Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by western
             blot before study entry

               -  HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a
                  method other than ELISA is acceptable as an alternative confirmatory test

          -  Meets 1 of the following criteria:

               -  Nadir CD4 level of ≤ 350 cells/mm³ and receiving highly active antiretroviral
                  therapy (HAART) for at least 6 months before study entry

               -  Nadir CD4 level of &gt; 350 cells/mm³ and not receiving HAART at the time of study
                  entry

          -  No known history of high-grade CIN or cervical cancer

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  ANC &gt; 750 cells/mm³

          -  Hemoglobin ≥ 9.0 g/dL

          -  Platelet count ≥ 100,000/mm³

          -  Serum creatinine ≤ 3 times upper limit of normal (ULN)

          -  AST and ALT ≤ 3.0 times ULN

          -  Conjugated (direct) bilirubin ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active drug or alcohol use or dependence that would interfere with adherence to
             study requirements, in the opinion of the site Investigator

          -  No serious illness requiring systemic treatment and/or hospitalization within the past
             45 days

          -  No allergy to yeast or any of the components of quadrivalent human papillomavirus
             (types 6, 11, 16, 18) recombinant vaccine

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 45 days since prior systemic antineoplastic or immunomodulatory treatment,
             systemic corticosteroids, investigational vaccines, interleukins, interferons, growth
             factors, or intravenous immunoglobulin

               -  Routine standard of care, including hepatitis B, influenza, and tetanus vaccines
                  are allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Palefsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N. Kumarasamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>YRG Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>YRG Care</name>
      <address>
        <city>Chennai</city>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>January 23, 2014</results_first_submitted>
  <results_first_submitted_qc>March 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2014</results_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human papilloma virus infection</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>cervical intraepithelial neoplasia</keyword>
  <keyword>HIV infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gardasil Vaccination</title>
          <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled in study</population>
      <group_list>
        <group group_id="B1">
          <title>Gardasil Vaccination</title>
          <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0</title>
        <description>Number of grade 3 or 4 adverse events attributed to vaccine per 100 patients</description>
        <time_frame>52 weeks from study entry</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccination</title>
            <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0</title>
          <description>Number of grade 3 or 4 adverse events attributed to vaccine per 100 patients</description>
          <population>Intent-to-treat</population>
          <units>Grade 3/4 adverse events per 100 patient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="3.12" upper_limit="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Significant Decrease (at the 0.05 Significance Level) in CD4+ Cell Count</title>
        <description>Significant decrease (at the 0.05 significance level) in CD4+ cell count to 75% of the baseline level on two or more consecutive tests</description>
        <time_frame>Screening/Week 0, Weeks 2, 10, 26, and 52.</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccination</title>
            <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Significant Decrease (at the 0.05 Significance Level) in CD4+ Cell Count</title>
          <description>Significant decrease (at the 0.05 significance level) in CD4+ cell count to 75% of the baseline level on two or more consecutive tests</description>
          <population>Intent-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="3.77" upper_limit="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Detectable HPV Antibodies to HPV 16 at Week 28</title>
        <description>Number of participants with detectable HPV antibody to HPV 16 among those with undetectable antibodies to HPV 16 at baseline</description>
        <time_frame>Week 28</time_frame>
        <population>Per-protocol population with undetectable HPV-16 levels at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccination</title>
            <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Detectable HPV Antibodies to HPV 16 at Week 28</title>
          <description>Number of participants with detectable HPV antibody to HPV 16 among those with undetectable antibodies to HPV 16 at baseline</description>
          <population>Per-protocol population with undetectable HPV-16 levels at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With a Significant Increase in HIV Viral Load</title>
        <description>Number of patients with a significant increase in HIV viral load defined as &gt; 1 log increase in HIV load from baseline on 2 consecutive occasions</description>
        <time_frame>Screening/week 0, weeks, 2, 10, 26 and 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccination</title>
            <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Significant Increase in HIV Viral Load</title>
          <description>Number of patients with a significant increase in HIV viral load defined as &gt; 1 log increase in HIV load from baseline on 2 consecutive occasions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="1.95" upper_limit="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Detectable Antibodies to HPV-6</title>
        <description>Detectable antibodies to HPV-6 among participant who had undetectable antibodies to HPV-6 at baseline</description>
        <time_frame>28 weeks</time_frame>
        <population>Per-protocol participants with undetectable antibodies to HPV-6 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccination</title>
            <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Detectable Antibodies to HPV-6</title>
          <description>Detectable antibodies to HPV-6 among participant who had undetectable antibodies to HPV-6 at baseline</description>
          <population>Per-protocol participants with undetectable antibodies to HPV-6 at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Detectable Antibodies to HPV-11</title>
        <description>Detectable antibodies to HPV-11 among those who had undetectable antibodies to HPV-11 at baseline</description>
        <time_frame>28 weeks</time_frame>
        <population>Per-protocol population of participants with undetectable antibodies for HPV-11 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccination</title>
            <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Detectable Antibodies to HPV-11</title>
          <description>Detectable antibodies to HPV-11 among those who had undetectable antibodies to HPV-11 at baseline</description>
          <population>Per-protocol population of participants with undetectable antibodies for HPV-11 at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Detectable Antibodies to HPV-18</title>
        <description>Detectable antibodies to HPV-18 among participants with undetectable antibodies to HPV-18 at baseline</description>
        <time_frame>28 weeks</time_frame>
        <population>Per-protocol population of participants with undetectable HPV-18 antibodies at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccination</title>
            <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Detectable Antibodies to HPV-18</title>
          <description>Detectable antibodies to HPV-18 among participants with undetectable antibodies to HPV-18 at baseline</description>
          <population>Per-protocol population of participants with undetectable HPV-18 antibodies at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gardasil Vaccination</title>
          <description>Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
DNA analysis: Weeks 0, 2, 10, 26, and 52.
polymerase chain reaction: Screening, week 36, and week 52.
cytology specimen collection procedure: Screening, week 36, and week 52.
colposcopic biopsy: Screening, week 36, and week 52.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="60" subjects_affected="44" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Vulval Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="40" subjects_affected="27" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="25" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="61" subjects_affected="45" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="87" subjects_affected="59" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="64" subjects_affected="41" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Rash, maculo-papular</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeannette Y. Lee</name_or_title>
      <organization>AMC</organization>
      <phone>5015266712</phone>
      <email>jylee@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

